Prognostic value of EMT-circulating tumor cells in metastatic breast can-cer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation
Genre
Journal ArticleDate
2012-12-10Author
Mego, MGao, H
Lee, BN
Cohen, EN
Tin, S
Giordano, A
Wu, Q
Liu, P
Nieto, Y
Champlin, RE
Hortobagyi, GN
Cristofanilli, M
Ueno, NT
Reuben, JM
Subject
metastatic breast cancercirculating tumor cells
epithelial-mesenchymal transition
high-dose chemotherapy
autologous hematopoietic stem cell transplantation
Permanent link to this record
http://hdl.handle.net/20.500.12613/5434
Metadata
Show full item recordDOI
10.7150/jca.5111Abstract
Background: Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer (MBC) patients treated by conventional dose chemotherapy. The aim of this study was to determine the role of CTCs and CTCs undergoing epitheli-al-mesenchymal transition (EMT) in metastatic breast cancer. We used the platform of high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (AHSCT) to study the CTCs and CTCs with EMT. Patients and methods: CTCs were enumerated in 21 MBC patients before apheresis and 1 month after AHSCT. CD34-depleted apheresis products were analyzed for CD326+ epi-thelial and Aldefluor+ cancer stem cells (CSC) by flow cytometry and were depleted of CD45+ cells and assessed for EMT-inducing transcription factors (EMT-TF) by quantitative RT-PCR. Results: Patients with ≥ 5 CTCs/7.5 mL of peripheral blood 1 month after AHSCT had shorter progression-free survival (PFS) (P=0.02) and overall survival (OS) (P=0.02). Patients with apheresis products containing high percentages of CD326+ epithelial cells or overex-pressing EMT-TF had shorter PFS. In multivariate analysis, low percentage of CD326+ epi-thelial cells and response to HDCT with AHSCT were associated with longer PFS, whereas lower CTCs after AHSCT was associated with longer OS. High CTCs, 1 month after AHSCT correlated with shorter PFS and OS in MBC patients undergoing HDCT and AHSCT, while CTCs with EMT and CSCs phenotype in apheresis products are associated with relapse. Conclusion: Our data suggest that CTC and CTCs with EMT are prognostic in MBC patients undergoing HDCT followed by AHSCT. © Ivyspring International Publisher.Citation to related work
Ivyspring International PublisherHas part
Journal of CancerADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/5416
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/